Piers Morgan has issued a warning to those who have taken aim at him amid his "Good Morning Britain" exit, tweeting, “I am watching and I will retaliate.”
Piers Morgan has issued a warning to those who have taken aim at him amid his "Good Morning Britain" exit, tweeting, “I am watching and I will retaliate.”
The BJP needs to club all Modi's rallies for the balance of two phases in a single day.
The "Flame Retardant Apparel Market Share, Size, Trends, Industry Analysis Report, By Product; By Type, By Clothing Type; By End-Use; By Regions; Segment Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
Our weekly roundup of books that should be on your radar.
Report titled “Pesticides Market in India- Macro Economy Impact Assessment & Outlook to 2025” provides a holistic perspective of past, present and future market performance. The report deep dives into various parameters including Pesticides market revenue, Production & Consumption volume, major segmentation by Type of Pesticides (Insecticides, Herbicides, Fungicides) and market distribution by Organised and Unorganised channels.New York, April 19, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Pesticides Market in India- Macro Economy Impact Assessment & Outlook to 2025" - https://www.reportlinker.com/p06037548/?utm_source=GNW Report also decodes demand by Crops and Regional consumption pattern. The study comprises of market dynamics which offers an understanding of the industry trends, driving forces, major challenges hampering the growth and also an analysis of the future opportunities which will help market players to leverage untapped business potential in the particular geography. In depth coverage of herbicides, fungicides and insecticides market would help the reader to gain insights on production and consumption of pesticides and so as to assess the reasons of the GAP. Key Players Discussed in the Report:United Phosphorus LtdBASFBayer IndiaSyngenta India Ltd.Dhanuka Agritech Ltd. Excel Crop Care Ltd.Rallis India LimitedRead the full report: https://www.reportlinker.com/p06037548/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
India is set to accept the Serum Institute of India's (SII) request for a grant of 30 billion rupees ($400 million) to boost its capacity to make the AstraZeneca COVID-19 vaccine, a government source with knowledge of the matter told Reuters. As coronavirus infections overwhelm the country, the government is struggling to meet demand for vaccine doses.
Dublin, April 19, 2021 (GLOBE NEWSWIRE) -- The "Global Solid Tumor Testing Market 2019-2030: Focus on Technology, Cancer Type, Application, End-user and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. This report highlights that the market is projected to reach $40.6 billion by 2030. The study also highlights that the market is set to witness a CAGR of 6.09% during the period 2020-2030. The market is driven by the need for the development of an advanced solution based on various technologies such as next-generation sequencing, in-situ hybridization, and polymerase chain reaction for cancer research in various applications such as diagnosis, prognosis, and treatment. The market is favored by the development of high-throughput, rapid, sensitive, and multi-parametric solutions for prognosis, diagnostics, and treatment. The gradual increase in the prevalence of cancer globally has furthered the solid tumor testing market. Furthermore, several contract research organizations are focusing on the development of solid tumor testing services, which enable to perform an extensive preclinical study at lower operation costs and less turn-around time. Within the research report, the market is segmented on the basis of cancer type, technology application, end-users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained. Competitive Landscape The exponential rise in the application of precision medicine on the global level has created a buzz among companies to invest in the development of high-resolution multiplex diagnostics providing information on cellular interaction and tissue heterogeneity to understand disease biology and pathology. Due to technologically advanced solutions and intense market penetration, companies such as Quest Diagnostics Incorporated have been a pioneer and a significant competitor in this market. Other key players in the market are Abbott Laboratories, Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Beijing Genomics Institute (BGI), QIAGEN N.V., ASURAGEN, Inc., NeoGenomics Laboratories, Inc., Invivoscribe, Inc., Inviate Corporation, Opko Health, Laboratory Corporation of American Holdings, OmniSeq, and Guardant Health. On the basis of region, North America holds the largest share of the global solid tumor testing market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region. The global solid tumor testing market utilizes technologies such as next-generation sequencing, in-situ hybridization, immunohistochemistry, polymerase chain reaction, and other technologies for the development of advanced diagnostic tools to cater to a holistic approach toward the treatment of cancer. The rising incidence of cancer and the increasing global burden of the disease has subsequently furthered the growth of the market. Key Questions Answered in this Report What are the major market drivers, challenges, and opportunities in the global solid tumor testing market?What is the potential impact of biotechnological advancements in the diagnostic industry among end-users such as researchers, pathologists, and laboratory technicians?What is the current market demand along with future expected demand for the global solid tumor testing market?What are the key development strategies that are implemented by the major players in order to sustain the competitive market?How is each segment of the market expected to grow during the forecast period 2020-2030?Which are the leading players with significant offerings to the global solid tumor testing market?What is the expected market dominance for each of these leading players?Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global solid tumor testing market? Key Topics Covered: 1 Product Definition1.1 Inclusion and Exclusion 2 Market Scope2.1 Scope of Work2.2 Key Questions Answered in the Report 3 Research Methodology3.1 Global Solid Tumors Testing Market: Research Methodology3.2 Primary Data Sources3.3 Secondary Data Sources3.4 Market Estimation Model3.5 Criteria for Company Profiling 4 Market Overview4.1 Definition4.2 Solid Tumor Testing Technologies4.3 Industry Participants Landscape4.4 Impact of COVID-19 on Delivery of Care for Cancer Patients 5 Industry Insights5.1 Regulation of Genetic Tests5.1.1 FDA Regulation5.1.2 CMS Regulation5.2 Legal Requirements and Framework in Europe5.3 Legal Requirements and Framework in Asia-Pacific5.3.1 China5.3.2 Japan5.4 Reimbursement Scenario5.4.1 Impact on Laboratory Industry 6 Market Dynamics6.1 Impact Analysis6.2 Market Drivers6.2.1 Rising Incidence of Cancers6.2.2 Decreasing Cost of Sequencing6.2.3 Increasing Adoption of Inorganic Growth Strategies in the Market6.2.4 Expected Increase in Adoption of Genetic Testing6.3 Market Restraints6.3.1 Uncertain Reimbursement Policies6.3.2 Requirement of High Capital Investment Hindering Expansion6.3.3 High Pricing Pressure6.4 Market Opportunities6.4.1 Massive Scope for Adoption of Genomic-Based Medicine in Emerging Nations6.4.2 Technological Advancements in the Field of Cancer Genomics6.4.3 Mushrooming Direct-to-Consumer (DTC) Testing Services Market6.4.4 Increasing Disposable Income in Emerging Economies 7 Competitive Landscape7.1 Key Strategies and Developments7.1.1 Synergistic Activities7.1.2 Approvals7.1.3 Product Launches, Enhancements, and Expansions7.1.4 Acquisitions and Mergers7.2 Product Scenario7.3 Market Share Analysis7.4 Growth-Share Analysis (Opportunity Mapping)7.4.1 By Company7.4.2 By Technology7.4.3 By Application7.4.4 By Cancer Type 8 Global Solid Tumor Testing Market (by Technology), $Million, 2019-20308.1 Overview8.2 Next-Generation Sequencing8.3 In Situ Hybridization8.4 Polymerase Chain Reaction8.5 Immunohistochemistry8.6 Other Technologies 9 Global Solid Tumor Testing Market (by Cancer Type), $Million, 2019-20309.1 Overview9.2 Breast Cancer9.3 Prostate Cancer9.4 Colorectal Cancer9.5 Lung Cancer9.6 Melanoma9.7 Endometrial Cancer9.8 Thyroid Cancer9.9 Brain Cancer9.1 Ovarian Cancer9.11 Liver Cancer9.12 Other Cancer Types 10 Global Solid Tumor Testing Market, by Application, $Million, 2019-203010.1 Overview10.2 Clinical10.3 Research 11 Global Solid Tumor Testing Market (by Region), $Million, 2019-203011.1 Overview11.2 North America11.2.1 U.S.11.2.2 Canada11.3 Europe11.3.1 Germany11.3.2 U.K.11.3.3 France11.3.4 Italy11.3.5 Spain11.3.6 Rest-of-Europe11.4 Asia-Pacific11.4.1 China11.4.2 Japan11.4.3 India11.4.4 Singapore11.4.5 Australia11.4.6 Rest-of-APAC11.5 Latin America11.5.1 Brazil11.5.2 Mexico11.5.3 Rest-of-LATAM11.6 Rest-of-the-World (RoW) 12 Global Solid Tumor Testing Market, by End User, $Million, 2019-203012.1 Overview12.2 Hospitals, Diagnostic Laboratories, and Reference Laboratories12.3 Pharmaceutical and Biotechnology Companies12.4 Contract Research Organizations12.5 Academic Research Institutions12.6 Other End Users 13 Company Profiles13.1 Overview13.2 Abbott Laboratories13.2.1 Company Overview13.2.2 Role of Abbott Laboratories in the Global Solid Tumor Testing Market13.2.3 Financials13.2.4 Key Insights About Financial Health of the Company13.2.5 SWOT Analysis13.3 ARUP Laboratories13.3.1 Company Overview13.3.2 Role of ARUP Laboratories in the Global Solid Tumor Testing Market13.3.3 SWOT Analysis13.4 ASURAGEN, INC.13.4.1 Company Overview13.4.2 Role of ASURAGEN, INC. in the Global Solid Tumor Testing Market13.4.3 SWOT Analysis13.5 Bio-Rad Laboratories, Inc.13.5.1 Company Overview13.5.2 Role of Bio-Rad Laboratories, Inc. in the Global Solid Tumor Testing Market13.5.3 Financials13.5.4 Key Insights About Financial Health of the Company13.5.5 SWOT Analysis13.6 Beijing Genomics Institute (BGI) Genomics Co., Ltd13.6.1 Company Overview13.6.2 Role of Beijing Genomics Institute (BGI) Genomics Co., Ltd in the Global Solid Tumor Testing Market13.6.3 SWOT Analysis13.7 F. Hoffmann-La Roche Ltd.13.7.1 Company Overview13.7.2 Role of F. Hoffmann-La Roche Ltd in the Global Solid Tumor Testing Market13.7.3 Financials13.7.4 Key Insights About Financial Health of the Company13.7.5 SWOT Analysis13.8 Guardant Health13.8.1 Company Overview13.8.2 Role of Guardant Health in the Global Solid Tumor Testing Market13.8.3 Financials13.8.4 SWOT Analysis13.9 Illumina, Inc.13.9.1 Company Overview13.9.2 Role of Illumina, Inc. in the Global Solid Tumor Testing Market13.9.3 Financials13.9.4 Key Insights About Financial Health of the Company13.9.5 SWOT Analysis13.1 Invivoscribe, Inc.13.10.1 Company Overview13.10.2 Role of Invivoscribe, Inc. in the Global Solid Tumor Testing Market13.10.3 SWOT Analysis13.11 Invitae Corporation13.11.1 Company Overview13.11.2 Role of Invitae Corporation, Inc. in the Global Solid Tumor Testing Market13.11.3 Financials13.11.4 Key Insights About Financial Health of the Company13.11.5 SWOT Analysis13.12 Laboratory Corporation of America Holdings13.12.1 Company Overview13.12.2 Role of Laboratory Corporation of America Holdings in the Global Solid Tumor Testing Market13.12.3 Financials13.12.4 SWOT Analysis13.13 NeoGenomics Laboratories, Inc.13.13.1 Company Overview13.13.2 Role of NeoGenomics Laboratories, Inc. in the Global Solid Tumor Testing Market13.13.3 Financials13.13.4 Key Insights About Financial Health of the Company13.13.5 SWOT Analysis13.14 Opko Health13.14.1 Company Overview13.14.2 Role of Opko Health, Inc. in the Global Solid Tumor Testing Market13.14.3 Financials13.14.4 Key Insights About Financial Health of the Company13.14.5 SWOT Analysis13.15 OmniSeq13.15.1 Company Overview13.15.2 Role of OmniSeq in the Global Solid Tumor Testing Market13.15.3 SWOT Analysis13.16 QIAGEN N.V.13.16.1 Company Overview13.16.2 Role of QIAGEN N.V. in the Global Solid Tumor Testing Market13.16.3 Financials13.16.4 Key Insights About Financial Health of the Company13.16.5 SWOT Analysis13.17 Quest Diagnostics Incorporated13.17.1 Company Overview13.17.2 Role of Quest Diagnostics Limited in the Global Solid Tumor Testing Market13.17.3 Financials13.17.4 SWOT Analysis For more information about this report visit https://www.researchandmarkets.com/r/2otjgb CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
The collision between Valtteri Bottas and George Russell in Sunday's Emilia Romagna Grand Prix could affect Mercedes' plans for developing their Formula One car this season, according to team boss Toto Wolff. The high-speed crash at Italy's Imola circuit wrecked both Bottas's Mercedes and Russell's Williams, though both drivers were not injured. "The whole situation is absolutely not amusing for us, to be honest," Wolff told reporters.
An inquest found that Harry’s death at the Queen Elizabeth The Queen Mother Hospital in Margate in November 2017 was ‘wholly avoidable’.
Market Performance North America is the third largest agrochemicals market in the world with the largest contribution from the US market in terms of revenue and volume. Canada has extreme weather conditions that restrict the crop production; while US is facing another set of challenges such as drought and reducing arable land that has created the need for agrochemicals such as pesticides to save crops and increase production in the limited area.New York, April 19, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "North America Crop Protection Chemicals Market Analysis Outlook to 2026" - https://www.reportlinker.com/p06020277/?utm_source=GNW Pesticides and fertilizers and the two major segments of the agrochemicals industry of which fertilizers account for almost 70% of the market. In North America, Corn, Soyabean, Cotton and Wheat are the major crops produced however in 2019 due to the climatic conditions and the US – China trade war, production of the crops declined. Demand for organic farming is rising worldwide and so as in North America. Rising health concerns, application of harmful chemicals in synthetic pesticides has given birth to organic farming. Rising awareness of enhanced farming practices and the US being one of the largest exporter of certain category of crops it becomes crucial to grow better quality of crops. Scope of the Study The synopsis presented has been derived from the report titled “North America Crop Protection Chemicals Market Analysis Outlook to 2026” published by Makreo Research and Consulting. The report provides a holistic perspective of past, present and future market performance. The report provides a comprehensive analysis of the US, Canada and Mexico crop production and application of crop protection chemicals. Report also decodes market by products (herbicides, insecticides, fungicides, and others), market by geographies (the US, Canada, Mexico), market segmentation by synthetic and bio-based pesticides. The report assesses future market performance and assess players performance during the review period. Key Players covered The key players covered in this report are: BASF SE Bayer Crop Science AG ADAMA Agricultural Solutions Syngenta AG Corteva Agri Science Nufam LTD American Vanguard Corporation Other Key Players Key Questions Answered - What is the Past, Present, and Future outlook of North America Crop Protection Market? - Discuss the market performance of Insecticides, Herbicides, Fungicides and Bio Pesticides Market, including historical performance, recent developments, and future projections - Discuss the analysis of North America Crop Protection market with respect to key application in major crops. - Discuss the analysis of North America Crop Protection market with respect to key application in major countries such as The US, Canada, Mexico. - Explain the Trade Analysis of Pesticides Industry. - Discuss detail examination of micro and macro dynamics, specifically growth enablers, market retardants, trends & development and major opportunities. - Discuss the Strategic Profiling of Major Players operating in the region.Read the full report: https://www.reportlinker.com/p06020277/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
The update could fix the delay in incoming calls while the phone is plugged into a charging port.
British retailer Marks & Spencer will increase its online capacity by building a new automated online warehouse in its existing distribution centre in Bradford, northern England, it said on Monday. M&S said the expansion would create 300 new jobs. The COVID-19 pandemic has accelerated the trend towards more digital shopping, with M&S's online sales growing 34% in the first half of its 2020-21 year.
MOSCOW — The Russian state penitentiary service said Monday a decision has been made to transfer imprisoned Russian opposition leader Alexei Navalny, who is in the third week of a hunger strike, to a hospital. The announcement comes two days after Navalny’s physician said his health was deteriorating rapidly and the 44-year-old Kremlin critic could be on the verge of death. The state prison service, FSIN, said in a statement that Navalny would be transferred to a hospital for convicts located in another penal colony in Vladimir, a city 180 kilometres (110 miles) east of Moscow. According to the statement, Navalny’s condition is deemed “satisfactory” and he has agreed to take vitamin therapy. Navalny’s physician, Dr. Yaroslav Ashikhmin, said Saturday that test results he received from Navalny’s family show him with sharply elevated levels of potassium, which can bring on cardiac arrest, and heightened creatinine levels that indicate impaired kidneys. “Our patient could die at any moment,” he said in a Facebook post. Navalny went on hunger strike to protest the refusal to let his doctors visit when he began experiencing severe back pain and a loss of feeling in his legs. Russia’s state penitentiary service has said that Navalny was receiving all the medical help he needs. In response to the alarming news about Navalny’s health this weekend, his allies have called for a nationwide rally on Wednesday, the same day that President Vladimir Putin is scheduled to deliver his annual state of the nation address. Navalny, Putin's fiercest opponent, was arrested in January upon his return from Germany, where he had spent five months recovering from a nerve agent poisoning he blames on the Kremlin — accusations Russian officials have rejected. Navalny’s arrest triggered a massive wave of protests all across Russia, the biggest show of defiance in recent years. Soon after the arrest, a court ordered Navalny to serve 2 1/2 years in prison on a 2014 embezzlement conviction he said was fabricated and the European Court of Human Rights deemed to be “arbitrary and manifestly unreasonable.” Last month, the politician was transferred to a penal colony east of Moscow, notorious for its harsh conditions. Navalny has complained about being sleep-deprived due to guards conducting hourly checks on him at night, and said he has developed severe back pain and numbness in his legs within weeks of being transferred to the colony. His demands for a visit from an independent “civilian” physician were rebuffed by prison officials, and he went on hunger strike on March 31. In a message from prison on Friday, Navalny said prison officials threatened to force-feed him “imminently,” using “straitjacket and other pleasures.” Daria Litvinova, The Associated Press
As COVID-19 vaccine supplies ramp up across the country, most provinces and territories have released details of who can expect to receive a shot in the coming weeks.The military commander handling logistics for Canada's vaccine distribution program says there will be enough vaccine delivered to give a first dose before Canada Day to every adult who wants one.Maj.-Gen. Dany Fortin says that's if provinces follow the advice to delay second doses up to four months.He also cautions that it is dependent on having no production delays again.Health Canada anticipates a total of 36.5 million doses from Pfizer-BioNTech, Moderna and the AstraZeneca vaccine from the Serum Institute of India by June 30.Most Canadian provinces have suspended use of the Oxford-AstraZeneca COVID-19 vaccine in people under age 55, acting on an advisory committee's concerns about a possible link between the shot and rare blood clots. However, Ontario and Alberta have lowered the age eligibility to those 40 and older.Dr. Heather Morrison, P.E.I.'s chief medical officer of health, said the risk of developing a serious problem after being immunized is "very, very low."She said people who received the AstraZeneca vaccine should look for symptoms such as shortness of breath, chest pain, leg swelling, persistent abdominal pain, sudden onset of severe or persistent headache or blurred vision and skin bruising elsewhere than the site of vaccination, developing four to 20 days after vaccination.There are approximately 31 million Canadians over 16, and no vaccines are approved for anyone younger than 16.Here's a list of the inoculation plans throughout Canada:Newfoundland and LabradorHealth officials say vaccinations have begun for first responders. Pre-registration for COVID-19 vaccines has opened for people aged 70 or older and for home-support workers.Last month Newfoundland and Labrador extended the interval between the first and second doses of the COVID-19 vaccine to four months.Public health officials said the change would help them vaccinate 40,000 more people with a single dose by the end of March.---Nova ScotiaAll Nova Scotians who want a vaccination should be able to get their first shot by late June, chief medical officer of health Dr. Robert Strang announced on April 9. The original target was September.Strang also said that as of April 9, Nova Scotians 65 years of age and older became eligible to receive their first dose. As well, the Oxford-AstraZeneca vaccine is still available for those 55 to 64 years old.The province is also planning to use mobile van clinics to vaccinate about 900 people who work at or use homeless shelters in the Halifax area.Public health is partnering with pharmacists and doctors to provide the vaccines at 25 locations.Nova Scotia, meanwhile, has added front-line police officers to the list of people eligible for vaccination during the second phase of the province's rollout plan, joining groups such as long-haul truck drivers and hospital workers over the age of 60.---Prince Edward IslandHealth officials in Prince Edward Island say they will shift their focus to getting a first dose of COVID-19 vaccine to all adults by July 1, even if it means delaying the second shot for some.P.E.I., meantime, has joined suspended administering the Oxford-AstraZeneca vaccine to people under age 55 due to concerns about a possible link between the shot and rare blood clots.---New BrunswickNew Brunswick health officials say people 70 and older, a caregiver or a family member acting on their behalf can now make an appointment for a vaccine at a pharmacy.Health-care professionals who have close contact with patients, and people with complex medical conditions are also eligible to receive a COVID-19 vaccine.The province says all residents of long-term care homes have been offered at least one dose of vaccine. As of March 19, all residents of First Nations communities aged 16 or older were given access to their first dose of vaccine.Workers who regularly travel across the border, including regular commuters, truckers and rotational workers are also eligible to receive vaccines.---QuebecQuebec has expanded access to COVID-19 vaccines to Montrealers who are essential workers or who have chronic illnesses.Essential workers such as teachers and first responders can now book an appointment after providing proof of employment.Quebecers between the ages of 55 and 79 can now receive an Oxford-AstraZeneca vaccine at walk-in clinics.Quebec has also opened vaccination appointments for anyone over the age of 60 across the province.Officials announced on April 8 the first 13 companies that will operate clinics in their workplaces, with each site able to vaccinate up to 25,000 people between May and August.Participating companies include National Bank, Bell, and Groupe CH, owner of the Montreal Canadiens NHL team. The clinics will be located in eight different health regions and should be operational by May 1.Montreal's airport authority will partner with Air Canada and Bombardier to create a vaccination hub that will operate two sites at the departure level of the airport terminal and in a nearby Bombardier hangar.---OntarioOntario is expanding the number of residents eligible to receive the Oxford-AstraZeneca vaccine.Starting Apr. 20 those 40 and older can start receiving the shot. The previous cut-off age was 55. Shots will be available through pharmacies and primary care providers.Ontario, meantime, is doubling the number of pharmacies involved in the provincial vaccine effort. Some 1,400 pharmacies in COVID-19 hot spots are now offering the Oxford-AstraZeneca vaccine. The province says it hopes to add another 100 pharmacies to the vaccine effort by the end of the month.Some residents of Toronto and Peel Region aged 50 and older can now book their COVID-19 vaccine appointments.Toronto says people who live in hot spot neighbourhoods can book an appointment to get their shot, while Peel has opened the bookings for anyone in the age group.The Ontario government said beginning April 5, people aged 60 and over could book their vaccine appointments in every region.---ManitobaManitoba is vaccinating people aged 57 and older in the general population, and First Nations people aged 37 and older. Health officials plan to continue reducing the age minimum age, bit by bit, over the coming months.Dr. Joss Reimer, medical lead of the province's vaccine task force, has said all adults in the province could have a first dose of by the end of June if supplies are steady.There are supersites in cities where people can get vaccines, and pop-up clinics have begun in rural and northern Manitoba communities for people who are eligible.Immunization teams have also been going to congregate living facilities, such as group homes, to provide vaccines.In the coming days Manitoba will prioritize firefighters and police officers for vaccines, as well as all adults living in high-risk areas, which have yet to be defined. Officials are promising details on Wednesday.Health officials say the province has capacity to deliver 20,000 doses each day, but are currently hindered by limited supply. They say all vaccines that arrive in the province are used within 10 days.---SaskatchewanThe Saskatchewan Health Authority is booking vaccinations for residents 48 and older. The minimum age drops to 40 for people living in the Far North.Additional health-care workers are now eligible for shots: staff in private doctors’ offices, private digital imaging clinics, community labs and the Saskatchewan cancer agency.The province has also expanded the vaccine delivery plan for people in more vulnerable groups to include all pregnant women and 16- and 17-year-olds who are considered clinically extremely vulnerable.The province has opened drive-thru vaccination clinics in communities across the province. In Regina, the drive-thru is available for people between the ages of 46 and 54. ---AlbertaAlbertans born in 2005 or earlier with high-risk underlying health conditions are eligible for shots.As of April 12, the next phase of health-care workers could book appointments: physicians, nurses, pharmacists, dentists, their office staff, lab workers, practicum students in clinical areas, as well as health workers on First Nations reserves and Metis settlements.Previously, shots have been available to front-line health workers, staff and residents in supportive living facilities, Albertans born in 1956 or earlier and First Nations, Inuit and Metis people born in 1971 or earlier.More than 250 pharmacies are now offering immunizations. And starting April 19, 10 physicians clinics across the province began providing shots as part of a pilot project, which could be expanded in May.Meanwhile, Premier Jason Kenney is lowering the minimum age for the Oxford-AstraZeneca vaccine from 55 down to those 40 and older.The change takes effect Tuesday (Apr. 20).Additional AstraZeneca vaccine appointments are available through Alberta Health Services in Edmonton and Calgary.Alberta has also said it is extending the time between the first dose and the second to four months.Health Minister Tyler Shandro has said the province expects to offer all Albertans 18 and over a first dose of vaccine by the end of June.---British ColumbiaB-C is lowering the eligibility age for people to register for COVID-19 vaccinations.The Ministry of Health says more than 1.8 million people are eligible to register for vaccines this week through the province's Get Vaccinated program.The ministry says people 40 years old and older are invited to register today (Apr. 19), with those 35 and older signing up Tuesday (Apr. 20) and 30 and older Wednesday (Apr. 21).Those 25 and older can register Thursday (Apr. 22) and 18 and above can sign up Friday (Apr.23).Once registered, users receive a confirmation code. They then wait for an email, text or call telling them they're eligible and can book their vaccine appointment using that code.B.C.'s age-based program runs parallel to its pharmacy-based vaccine drive for residents between the ages of 55 and 65 who are eligible for the Oxford-AstraZeneca shot. That program began for people living in the Lower Mainland but has since been made provincewide. The pharmacy program was developed after provincial health officer Dr. Bonnie Henry placed a pause on use of the AstraZeneca vaccine for anyone under 55 on the advice of the National Advisory Committee on Immunization over concerns about rare blood clots.Adults living and working in Whistler started receiving their COVID-19 vaccinations on Apr. 12.Firefighters, police and paramedics, meanwhile, are being vaccinated with the Pfizer-BioNTech and Moderna vaccines alongside staff at schools and childcare centres.Henry says certain neighbourhoods will also be targeted.The government says more than 1.2 million doses of COVID-19 vaccines have been administered in B.C.---NunavutNunavut has opened vaccinations to anyone 18 and older.The territory expects to finish its vaccine rollout of first and second doses by the end of April.---Northwest TerritoriesThe Northwest Territories is also providing vaccine to those 18 and older and expects to finish its rollout by the end of April.---YukonThe Yukon government says nearly 46 per cent of the territory's residents have now been fully vaccinated against COVID-19.Priority for vaccinations has been given to residents and staff in long-term care homes, group homes and shelters, as well as health-care workers and personal support workers. People over the age of 80 who are not living in long-term care, and those living in rural and remote communities, including Indigenous Peoples, are also on the priority list for shots.---This report by The Canadian Press was first published April 19, 2021. The Canadian Press
LONDON — British Prime Minister Boris Johnson has called off a trip to India amid surging coronavirus cases in the country. The British and Indian governments said Monday that “in the light of the current coronavirus situation, Prime Minister Boris Johnson will not be able to travel to India next week” as planned. The two governments said Johnson and Indian Prime Minister Narenda Modi would speak later this month and planned to meet in person later this year. The long-planned trip would have been Johnson’s first foreign visit since the start of the coronavirus pandemic more than a year ago. It was originally scheduled for January but postponed when infections soared in Britain. India reported 273,810 new infections on Monday, its highest daily rise since the start of the pandemic and now has reported more than 15 million infections, a total second only to the United States. The Health Ministry also reported 1,619 deaths from COVID-19 in the past 24 hours, pushing the toll over 178,769. India has the fourth-highest number of deaths after the U.S., Brazil and Mexico — though, with nearly 1.4 billion people, it has a much larger population than any of those countries. ___ Follow AP’s pandemic coverage at: https://apnews.com/hub/coronavirus-pandemic https://apnews.com/hub/coronavirus-vaccine https://apnews.com/UnderstandingtheOutbreak The Associated Press
TOKYO — Global shares were mixed and U.S. futures declined Monday amid cautious optimism about a global rebound from the coronavirus pandemic. Investors are awaiting a raft of earnings reports this week that will provide further fodder about how businesses are faring. France's CAC 40 added 0.3% in early trading to 6,305.64, while Germany's DAX inched down less than 0.1% to 15,457.17. Britain's FTSE 100 edged up 0.1% to 7,028.72. U.S. shares were set for a slow start to the week, with Dow futures down 0.3% and the future for the S&P 500 0.2% lower. Japan's benchmark closed less than 0.1% higher at 29,685.37, in the first Tokyo market reaction to a weekend by Prime Minister Yoshihide Suga with President Joe Biden over the weekend. Suga also spoke with the Pfizer chief executive, asking to ensure a more steady supply of the company's COVID-19 vaccine. Japan has lagged the U.S., Israel and some European nations in a vaccine rollout, with barely 1% of its population inoculated so far. The government measures against COVID-19 infections already in some urban areas, including Tokyo, are being expanded to other areas of Japan, starting Tuesday, but the cities of Tokyo and Osaka are considering strengthening them to a “state of emergency.” Japan has never had a lockdown, and its laws would need to be changed for such action. Australia's S&P/ASX 200 inched up less than 0.1% to 7,065.60, while South Korea's Kospi also was little changed, at 3,198.84. Hong Kong's Hang Seng rose 0.5% to 29,106.15. The Shanghai Composite gained 1.5% to 3,477.55. Even though the possibility of faster delivery of vaccines was a plus, the summit between Biden and Suga has added to tension with China, noted Yoshimasa Maruyama, chief market economist at SMBC Nikko Securities. “The Suga administration has taken a risk in China relations, in accordance to the U.S. request,” Maruyama said. Suga may have hoped Biden would more forcefully express support for the Tokyo Olympics, set to open in July despite widespread public objections and worries about the pandemic, but their joint statement merely said the U.S. supports Japan's "efforts to hold a safe and secure" Games. COVID-19 vaccinations, now reaching half of the U.S. population, and massive support from the U.S. government and Federal Reserve are fueling expectations for solid corporate profit growth as more businesses reopen. The last round of stimulus from the government helped lift retail sales, and investors now have to weigh other proposals in Washington, which include investments in infrastructure and potential tax changes. Investors also are focusing on earnings, with dozens of U.S. companies due to report results this week, including Coca-Cola, Johnson & Johnson, Verizon Communications, Dow Chemical and American Airlines. In energy trading, benchmark U.S. crude fell 7 cents to $63.12 a barrel in electronic trading on the New York Mercantile Exchange. It lost 32 cents to $63.19 per barrel on Friday. Brent crude, the international standard, was unchanged at $66.77 a barrel. In currency trading, the U.S. dollar edged down to 108.07 Japanese yen from 108.78 yen late Friday. The euro rose to $1.2022 from $1.1978. Yuri Kageyama, The Associated Press
Bank chief Noel Quinn says the "new reality of life" is people will not be in the office five days a week.
The announcement on Sunday has rocked football.
Dublin, April 19, 2021 (GLOBE NEWSWIRE) -- The "PVC Roofing Membrane Market Report: Trends, Forecast and Competitive Analysis" report has been added to ResearchAndMarkets.com's offering. The future of the PVC roofing membrane market looks promising with opportunities in the commercial, residential, and industrial sectors. The global PVC roofing membrane market is forecast to reach an estimated $1.9 billion by 2026 with a CAGR of 3.5% from 2020 to 2026. The major drivers for this market are growth in building and construction industry and stringent government regulation for energy efficiency. Carlisle Companies, Dow Chemical Company, Sika AG, Duro-Last Inc., and GAF are among the major PVC roofing membrane manufacturers.The study includes trends and forecasts for the global PVC Roofing Membrane market by end use industry, installation type, and region. The analyst forecasts that mechanically attached will remain the largest segment during the forecast period as it is most common installation method due to its low cost and ease of installation.Commercial will remain the largest end use industry during the forecast period due to the growing demand for energy efficient roofing in commercial buildings.Europe will remain the largest region by value and volume during the forecast period due to stringent government regulations, building codes for energy efficiency, and growth in retrofit building and construction market. Features of PVC Roofing Membrane Market Market Size Estimates: PVC Roofing membrane market size estimation in terms of value ($M) and volume (Million Square Meter )Trend and Forecast Analysis: Market trends (2015-2020) and forecast (2021-2026) by various segments and regions.Segmentation Analysis: Market size by installation type and end use industryRegional Analysis: PVC Roofing membrane market breakdown by North America, Europe, Asia Pacific, and the Rest of the World.Growth Opportunities: Analysis on growth opportunities in different end use industry, installation type, and regions for PVC Roofing membrane market.Strategic Analysis: This includes M&A, new product development, and competitive landscape for the PVC Roofing membrane market.Analysis of competitive intensity of the industry based on Porter's Five Forces model. This report answers following key questions Which segments will grow at a faster pace and why?Which regions will grow at a faster pace and why?What are the key factors affecting market dynamics? What are the drivers and challenges of the PVC roofing membrane market?What are the business risks and threats to the PVC roofing membrane market?What are emerging trends in the PVC roofing membrane market and the reasons behind them?What are some changing demands of customers in the PVC roofing membrane market?What are the new developments in the PVC roofing membrane market? Which companies are leading these developments?Who are the major players in the PVC roofing membrane market? What strategic initiatives are being implemented by key players for business growth?What are some of the competitive products and processes in the PVC roofing membrane market, and how big of a threat do they pose for loss of market share via material or product substitution?What M&A activities did take place in the last five years in the PVC roofing membrane market? Key Topics Covered: 1. Executive Summary2. Market Background and Classifications2.1: Introduction, Background, and Classifications2.2: Supply Chain2.3: Industry Drivers and Challenges3. Market Trends and Forecast Analysis from 2015 to 20263.1: Macroeconomic Trends (2015-2020) and Forecast (2021-2026)3.2: Global PVC Roofing Membrane Market Trends (2015-2020) and Forecast (2020-2026)3.3: Global PVC Roofing Membrane Market by End Use Industry3.3.1: Commercial3.3.2: Residential3.3.3: Industrial and Others3.4: Global PVC Roofing Membrane Market by Installation Type3.4.1: Mechanically Attached3.4.2: Ballasted3.4.3: Fully Adhered3.4.4: Others4. Market Trends and Forecast Analysis by Region from 2015 to 20264.1: Global PVC Roofing Membrane Market by Region4.2: North American PVC Roofing Membrane Market4.2.1: Market by End Use Industry4.2.2: Market by Installation Type4.3: European PVC Roofing Membrane Market4.3.1: Market by End Use Industry4.3.2: Market by Installation Type4.4: APAC PVC Roofing Membrane Market4.4.1: Market by End Use Industry4.4.2: Market by Installation Type4.5: ROW PVC Roofing Membrane Market4.5.1: Market by End Use Industry4.5.2: Market by Installation Type5. Competitor Analysis5.1: Product Portfolio Analysis5.2: Geographical Reach5.3: Porter's Five Forces Analysis6. Growth Opportunities and Strategic Analysis6.1: Growth Opportunity Analysis6.1.1: Growth Opportunities for the Global PVC Roofing Membrane Market by End Use Industry6.1.2: Growth Opportunities for the Global PVC Roofing Membrane Market by Installation Type6.1.3: Growth Opportunities for the Global PVC Roofing Membrane Market by Region6.2: Strategic Analysis6.2.1: New Product Development6.2.2: Mergers and Acquisitions in the Global PVC Roofing Membrane Industry6.2.3: Capacity Expansion of the Global PVC Roofing Membrane Market7. Company Profiles of Leading Players7.1: Carlisle Companies7.2: Dow Chemical Company7.3: Duro-Last Inc.7.4: GAF Materials7.5: Johns Manville7.6: Firestone Building Products7.7: Sika AG7.8: Godfrey Roofing Inc.7.9: SOPREMA Group7.10: Fatra, AS7.11: Technonicol7.12: Alwitra7.13: Protan7.14: BAUDER7.15: FLACHDACH7.16: RENOLIT7.17: Imper7.18: PolyglassFor more information about this report visit https://www.researchandmarkets.com/r/j5eq9l CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Portuguese leaves the club seventh in the Premier League, with Sunday’s Carabao Cup final looming
The "Access Control System Market Share, Size, Trends, Industry Analysis Report, By Type [Hardware, Software, Services]; By End Use; By Regions; Segment Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.